SEARCH:   Advanced

Blood, 1 January 2005, Vol. 105, No. 1, pp. 301-307. Prepublished online as a Blood First Edition Paper on September 2, 2004; DOI 10.1182/blood-2004-06-2298. This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 2004-06-2298v1 105/1/301    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Glas, A. M. Articles by de Jong, D. Search for Related Content PubMed PubMed Citation Articles by Glas, A. M. Articles by de Jong, D. Related Collections Neoplasia Oncogenes and Tumor Suppressors Signal Transduction Chemokines, Cytokines, and Interleukins Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment Annuska M. Glas, Marie José Kersten, Leonie J. M. J. Delahaye, Anke T. Witteveen, Robby E. Kibbelaar, Arno Velds, Lodewyk F. A. Wessels, Peter Joosten, Ron M. Kerkhoven, René Bernards, Johan H. J. M. van Krieken, Philip M. Kluin, Laura J. van't Veer, and Daphne de Jong From the Netherlands Cancer Institute, Divisions of Diagnostic Oncology, Medical Oncology, Central Microarray Facility, Amsterdam, The Netherlands; Academic Medical Center, Amsterdam, The Netherlands; Central Laboratory for Public Health Friesland, Leeuwarden, The Netherlands; Friesland Medical Center Leeuwarden, Leeuwarden, The Netherlands; Delft University of Technology, Delft, The Netherlands; University Medical Center Nijmegen, Nijmegen, The Netherlands; and Groningen University Medical Center, Groningen, The Netherlands. Follicular lymphoma (FL) is a disease characterized by a long clinical course marked by frequent relapses that vary in clinical aggressiveness over time. Therefore, the main dilemma at each relapse is the choice for the most effective treatment for optimal disease control and failure-free survival while at the same time avoiding overtreatment and harmful side effects. The selection for more aggressive treatment is currently based on histologic grading and clinical criteria; however, in up to 30% of all cases these methods prove to be insufficient. Using supervised classification on a training set of paired samples from patients who experienced either an indolent or aggressive disease course, a gene expression profile of 81 genes was established that could, with an accuracy of 100%, distinguish low-grade from high-grade disease. This profile accurately classified 93% of the FL samples in an independent validation set. Most important, in a third series of FL cases where histologic grading was ambiguous, precluding meaningful morphologic guidance, the 81-gene profile shows a classification accuracy of 94%. The FL stratification profile is a more reliable marker of clinical behavior than the currently used histologic grading and clinical criteria and may provide an important alternative to guide the choice of therapy in patients with FL both at presentation and at relapse. (Blood. 2005;105:301-307) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Carlotti and J. G. Gribben Stem cell mimicry: key to transformation? Blood, October 8, 2009; 114(15): 3133 - 3134. [Abstract] [Full Text] [PDF] A. J. Gentles, A. A. Alizadeh, S.-I. Lee, J. H. Myklebust, C. M. Shachaf, B. Shahbaba, R. Levy, D. Koller, and S. K. Plevritis A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients Blood, October 8, 2009; 114(15): 3158 - 3166. [Abstract] [Full Text] [PDF] M. Federico, M. Bellei, L. Marcheselli, S. Luminari, A. Lopez-Guillermo, U. Vitolo, B. Pro, S. Pileri, A. Pulsoni, P. Soubeyran, et al. Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project J. Clin. Oncol., September 20, 2009; 27(27): 4555 - 4562. [Abstract] [Full Text] [PDF] S. Middendorp, Y. Xiao, J.-Y. Song, V. Peperzak, P. H. L. Krijger, H. Jacobs, and J. Borst Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma Blood, September 10, 2009; 114(11): 2280 - 2289. [Abstract] [Full Text] [PDF] E. Leich, I. Salaverria, S. Bea, A. Zettl, G. Wright, V. Moreno, R. D. Gascoyne, W.-C. Chan, R. M. Braziel, L. M. Rimsza, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations Blood, July 23, 2009; 114(4): 826 - 834. [Abstract] [Full Text] [PDF] J. Carreras, A. Lopez-Guillermo, G. Roncador, N. Villamor, L. Colomo, A. Martinez, R. Hamoudi, W. J. Howat, E. Montserrat, and E. Campo High Numbers of Tumor-Infiltrating Programmed Cell Death 1-Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma J. Clin. Oncol., March 20, 2009; 27(9): 1470 - 1476. [Abstract] [Full Text] [PDF] M. Bendandi Aiming at a Curative Strategy for Follicular Lymphoma CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317. [Abstract] [Full Text] [PDF] N. A. Johnson and R. D. Gascoyne Gene expression signatures in follicular lymphoma: are they ready for the clinic? Haematologica, July 1, 2008; 93(7): 982 - 987. [Full Text] [PDF] P. P. Piccaluga, A. Califano, U. Klein, C. Agostinelli, B. Bellosillo, E. Gimeno, S. Serrano, F. Sole, Y. Zang, B. Falini, et al. Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas Haematologica, July 1, 2008; 93(7): 1033 - 1038. [Abstract] [Full Text] [PDF] S. S. Dave Follicular lymphoma and the microenvironment Blood, May 1, 2008; 111(9): 4427 - 4428. [Full Text] [PDF] R. J. Byers, E. Sakhinia, P. Joseph, C. Glennie, J. A. Hoyland, L. P. Menasce, J. A. Radford, and T. Illidge Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling Blood, May 1, 2008; 111(9): 4764 - 4770. [Abstract] [Full Text] [PDF] D. Canioni, G. Salles, N. Mounier, N. Brousse, M. Keuppens, F. Morchhauser, T. Lamy, A. Sonet, M.-C. Rousselet, C. Foussard, et al. High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial J. Clin. Oncol., January 20, 2008; 26(3): 440 - 446. [Abstract] [Full Text] [PDF] D. LeBrun, T. Baetz, C. Foster, P. Farmer, R. Sidhu, H. Guo, K. Harrison, R. Somogyi, L. D. Greller, and H. Feilotter Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs Clin. Cancer Res., January 15, 2008; 14(2): 478 - 487. [Abstract] [Full Text] [PDF] N. Schmitz, P. Dreger, B. Glass, and A. Sureda Allogeneic transplantation in lymphoma: current status Haematologica, November 1, 2007; 92(11): 1533 - 1548. [Abstract] [Full Text] [PDF] M. Taskinen, M.-L. Karjalainen-Lindsberg, H. Nyman, L.-M. Eerola, and S. Leppa A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone Clin. Cancer Res., October 1, 2007; 13(19): 5784 - 5789. [Abstract] [Full Text] [PDF] W. Klapper, E. Hoster, L. Rolver, C. Schrader, D. Janssen, M. Tiemann, H.-W. Bernd, O. Determann, M.-L. Hansmann, P. Moller, et al. Tumor Sclerosis but Not Cell Proliferation or Malignancy Grade Is a Prognostic Marker in Advanced-Stage Follicular Lymphoma: The German Low Grade Lymphoma Study Group J. Clin. Oncol., August 1, 2007; 25(22): 3330 - 3336. [Abstract] [Full Text] [PDF] J. R. Cerhan, S. Wang, M. J. Maurer, S. M. Ansell, S. M. Geyer, W. Cozen, L. M. Morton, S. Davis, R. K. Severson, N. Rothman, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival Blood, June 15, 2007; 109(12): 5439 - 5446. [Abstract] [Full Text] [PDF] A. M. Glas, L. Knoops, L. Delahaye, M. J. Kersten, R. E. Kibbelaar, L. A. Wessels, R. van Laar, J. H. J.M. van Krieken, J. W. Baars, J. Raemaekers, et al. Gene-Expression and Immunohistochemical Study of Specific T-Cell Subsets and Accessory Cell Types in the Transformation and Prognosis of Follicular Lymphoma J. Clin. Oncol., February 1, 2007; 25(4): 390 - 398. [Abstract] [Full Text] [PDF] B. E. Wahlin, B. Sander, B. Christensson, and E. Kimby CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma Clin. Cancer Res., January 15, 2007; 13(2): 388 - 397. [Abstract] [Full Text] [PDF] T. Alvaro, M. Lejeune, M.-T. Salvado, C. Lopez, J. Jaen, R. Bosch, and L. E. Pons Immunohistochemical Patterns of Reactive Microenvironment Are Associated With Clinicobiologic Behavior in Follicular Lymphoma Patients J. Clin. Oncol., December 1, 2006; 24(34): 5350 - 5357. [Abstract] [Full Text] [PDF] J. Carreras, A. Lopez-Guillermo, B. C. Fox, L. Colomo, A. Martinez, G. Roncador, E. Montserrat, E. Campo, and A. H. Banham High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma Blood, November 1, 2006; 108(9): 2957 - 2964. [Abstract] [Full Text] [PDF] B. Kreike, H. Halfwerk, P. Kristel, A. Glas, H. Peterse, H. Bartelink, and M. J. van de Vijver Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin. Cancer Res., October 1, 2006; 12(19): 5705 - 5712. [Abstract] [Full Text] [PDF] M. Booman, J. Douwes, A. M. Glas, S. A. Riemersma, E. S. Jordanova, K. Kok, A. Rosenwald, D. de Jong, E. Schuuring, and P. M. Kluin Mechanisms and Effects of Loss of Human Leukocyte Antigen Class II Expression in Immune-Privileged Site-Associated B-Cell Lymphoma. Clin. Cancer Res., May 1, 2006; 12(9): 2698 - 2705. [Abstract] [Full Text] [PDF] L. H. Sehn Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 295 - 302. [Abstract] [Full Text] [PDF] D. de Jong Molecular Pathogenesis of Follicular Lymphoma: A Cross Talk of Genetic and Immunologic Factors J. Clin. Oncol., September 10, 2005; 23(26): 6358 - 6363. [Abstract] [Full Text] [PDF] C. Gulmann, V. Espina, E. Petricoin III, D. L. Longo, M. Santi, T. Knutsen, M. Raffeld, E. S. Jaffe, L. A. Liotta, and A. L. Feldman Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma Clin. Cancer Res., August 15, 2005; 11(16): 5847 - 5855. [Abstract] [Full Text] [PDF] R. D. Gascoyne Hematopathology Approaches to Diagnosis and Prognosis of Indolent B-Cell Lymphomas Hematology, January 1, 2005; 2005(1): 299 - 306. [Abstract] [Full Text] [PDF] A. S. Freedman Biology and Management of Histologic Transformation of Indolent Lymphoma Hematology, January 1, 2005; 2005(1): 314 - 320. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020